APPLICATION OF ANTIPSYCHOTICS OF LONG-TERM ACTION IN SCHIZOPHRENIA
https://doi.org/10.21886/2219-8075-2020-11-1-6-13
Abstract
This literature review addresses the effectiveness and safety of long-acting antipsychotic therapy for schizophrenia. The results of randomized trials of recent years are described in detail. The efficacy of taking drugs at the following key research points was examined: the general clinical impression of the severity of the condition (CGI-S), the general clinical impression of the change in state during treatment (CGI-I), and the positive and negative syndrome scale (PANSS). A systematic literature search was conducted using the Scopus, Web of Science, MedLine, elibrary, and other databases.
About the Authors
Zh. B. Bibekova
Karaganda Medical University
Kazakhstan
Kazakhstan
Zhazira B. Bibekova — assistant of Neurology, neurosurgery, psychiatry and rehabilitology department.
Karaganda
E. A. Strel’cov
Karaganda Medical University
Kazakhstan
Kazakhstan
Evgeny A. Strel’tsov — resident doctor of Neurology, neurosurgery, psychiatry and rehabilitology department.
Karaganda
A. S. Makarchuk
Karaganda Medical University
Kazakhstan
Kazakhstan
Anton S. Makarchuk — resident doctor of Neurology, neurosurgery, psychiatry and rehabilitology department.
Karaganda
References
1. Karam CS, Ballon JS, Bivens NM, Freyberg Z, Girgis RR, et al. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci. 2010;31(8):381– 90. doi: 10.1016/j.tips.2010.05.004
2. Xu Y, Ren J, Ye H. Association between variations in the disrupted in schizophrenia 1 gene and schizophrenia: A meta-analysis. Gene. 2018;651:94–99. doi: 10.1016/j. gene.2018.01.069.
3. National Institute of Mental Health Schizophrenia. Available online: https://www.nimh.nih.gov/health/topics/ schizophrenia/index.shtml. (accessed on 1 February 2016)
4. Zhong X, Shi H, Hou L, Chen B, Peng Q, et al. Neuropsychiatric features of Neurosyphilis: frequency, relationship with the severity of cognitive impairment and comparison with Alzheimer disease. Dement Geriatr Cogn Disord. 2017;43(5– 6):308–319. doi: 10.1159/000476060.
5. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86–97. doi: 10.1016/S0140-6736(15)01121- 6
6. Laursen TM. Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res. 2011;131(1–3):101–4. doi: 10.1016/j.schres.2011.06.008
7. Leng CH, Chou MH, Lin SH, Yang YK, Wang JD. Estimation of life expectancy, loss-of-life expectancy, and lifetime health- care expenditures for schizophrenia in Taiwan. Schizophr Res. 2016;171(1–3):97–102. doi: 10.1016/j.schres.2016.01.033
8. Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Pre- mature Mortality Among Adults With Schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172–81. doi: 10.1001/jamapsychiatry.2015.1737
9. Walker ER, McGee RE, Druss BG. Mortality in mental dis- orders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334- 41. doi: 10.1001/jamapsychiatry.2014.2502
10. GBD 2016 Disease and Injury Incidence and Prevalence Col- laborators.. Global, regional, and national incidence, preva- lence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the global burden of disease study 2016. Lancet. 2017;390 (10100):1211–1259. doi: 10.1016/S0140-6736(17)32154-2.
11. Robertson L. Mental Health Matters. Volume 4. Health Ser- vice; Gauteng, South Africa; 2017.
12. Stringer J.L. Antipsychotics or Neuroleptics. In: Stringer J.L., ed. Basic Concepts in Pharmacology: What You Need to Know for Each Drug Class. 5th ed. McGraw-Hill; New York, NY, USA: Available at: http://accessmedicine.mhmedical.com/ content.aspx?bookid=2147§ionid=161351718. [accessed on 7 March 2019].
13. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892–909. doi: 10.4088/jcp.v63n1007
14. Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10:2. doi: 10.1186/1471-244X-10-2.
15. Di Lorenzo R, Ferri P, Cameli M, Rovesti S, Piemonte C. Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real- world clinical setting. Neuropsychiatr Dis Treat. 2019;15:183- 198. doi: 10.2147/NDT.S189245.
16. Gabriel R, Wojtanowicz T, Farokhpay R, Bota R. Acute transaminitis after initial days of starting haloperidol. Ment Illn. 2019;11(1):8113. doi: 10.4081/mi.2019.8113.
17. European Medicines Agency. Haldol Decanoate and Associated Names: Assessment Report. 2017. Committee for Medicinal Products for Human Use (CHMP).) (EMA/217985/2017). Available at: http://www.ema.europa.eu [accessed on 7 March 2019].
18. Taylor DM, Sparshatt A, O’Hagan M, Dzahini O. Effect of paliperidone palmitate on hospitalisation in a naturalistic cohort - a four-year mirror image study. Eur Psychiatry. 2016;37:43–48. doi: 10.1016/j.eurpsy.2016.04.009
19. McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA et all. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA. 2014;311(19):1978-87. doi: 10.1001/jama.2014.4310.
20. Mace S, Dzahini O, O’Hagan M, Taylor D. Haloperidol decanoate long-acting injection (HDLAI): Results of a 1-year mirror-image study. Ther Adv Psychopharmacol. 2018;8(9):241-249. doi: 10.1177/2045125318767587
21. Hori H, Katsuki A, Atake K, Yoshimura R. Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study. Front Psychiatry. 2018;9:74. doi: 10.3389/fpsyt.2018.00074
22. Mihaljevic-Peles A, Sagud M, Filipcic IS, Grosic V, Pedisic I, Emsley R. Remission and employment status in schizophrenia and other psychoses: One-year prospective study in Croatian patients treated with risperidone long acting injection. Psychiatr Danub. 2016;28(3):263-272. PMID: 27658835
23. Giraud-Baro E, Dassa D, De Vathaire F, Garay RP, Obeid J. Schizophrenia-spectrum patients treated with long-acting injectable risperidone in real-life clinical settings: functional recovery in remitted versus stable, non-remitted patients (the EVeREST prospective observational cohort study). BMC Psychiatry. 2016;16:8. doi: 10.1186/s12888-016-0712-1.
24. Jang S., Woo J. Five month-persistent extrapyramidal symptoms following a single injection of paliperidone palmitate: a case report. Clinical Psychopharmacology and Neuroscience. 2017;15(3):288–291. doi: 10.9758/ cpn.2017.15.3.288
25. Emsley R, Parellada E, Bioque M, Herrera B, Hernando T, Garcia-Dorado M. Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies. Int Clin Psychopharmacol. 2018;33(1):15–33. doi:10.1097/YIC.000000000000019
26. Li N, Feng Y, Lu H, Cai SL, Zhuo J, et al. Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics. Neuropsychiatr Dis Treat. 2018;14:825-837. doi: 10.2147/NDT.S158353
27. Fernández-Miranda JJ., Díaz-Fernández S. Tolerability of effective high doses of paliperidone palmitate in patients with severe resistant schizophrenia. International Clinical Psychopharmacology. 2017;32(1):6–12. doi: 10.1097/ YIC.0000000000000151
28. Si T, Zhuo J, Feng Y, Lu H, Hong D, Zhang L. Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia. Neuropsychiatr Dis Treat. 2019;15:1685-1694. doi: 10.2147/ NDT.S191803
29. Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, et al. Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. Neuropsychiatr Dis Treat. 2019;15:1365-1379. doi: 10.2147/NDT.S197225
30. Nash AI, Turkoz I, Savitz AJ, Mathews M, Kim E. Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation. Neuropsychiatr Dis Treat. 2019;15:731-737. doi: 10.2147/NDT.S194264
31. Mathews M, Nuamah I, Savitz AJ, Hough DW, Najarian D, et al. Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate. Neuropsychiatr Dis Treat. 2018;14:2807-2816. doi: 10.2147/ NDT.S175364
32. Gopal S, Vermeulen A, Nandy P, Ravenstijn P, Nuamah I, et al. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. Current Medical Resident Opinion. 2015;31(11):2043–2054. doi: 10.1185/03007995.2015.1085849
33. Hard ML, Wehr AY, Du Y, Weiden PJ, Walling D, von Moltke L. Pharmacokinetic evaluation of a 1-day treatment initiation option for starting long-acting aripiprazole lauroxil for schizophrenia. J Clin Psychopharmacol. 2018;38(5):435–441. doi: 10.1097/JCP.0000000000000921
34. McEvoy JP, Risinger R, Mykhnyak S, Du Y, Liu CC, Stanford AD. Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia. J Clin Psychiatry. 2017;78(8):1103-1109. doi: 10.4088/ JCP.17m11625.
35. Risinger R, Hard M, Weiden PJ. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil. Psychopharmacol Bull. 2017;47(3):26-34. PMID: 28839337
36. Cameron C, Zummo J, Desai DN, Drake C, Hutton B, Kotb A. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison. Value Health. 2017;20(7):876-885. doi: 10.1016/j.jval.2017.03.010
37. Nasrallah HA, Aquila R, Du Y, Stanford AD, Claxton A, Weiden PJ. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. CNS Spectr. 2019;24(4):395-403. doi: 10.1017/S1092852918001104
38. Mogwitz S, Buse J, Wolff N, Roessner V. Update on the Pharmacological Treatment of Tics with Dopamine- Modulating Agents. ACS Chem Neurosci. 2018;9(4):651-672. doi: 10.1021/acschemneuro.7b00460
39. Zhao YJ, Lin L, Teng M, Khoo AL, Soh LB, et al. Long- term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials. BJPsych Open. 2016;2(1):59-66. doi: 10.1192/bjpo. bp.115.002576
40. Maayan N, Quraishi SN, David A, Jayaswal A, Eisenbruch M, et al. Fluphenazine decanoate (depot) and enanthate for schizophrenia. Cochrane Database Syst Rev. 2015;(2):CD000307. doi: 10.1002/14651858.CD000307.pub2.
41. Coutinho E, Fenton M, Quraishi S. Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev. 2000;(2):CD001164. doi: 10.1002/14651858.CD001164
42. Mahapatra J, Quraishi SN, David A, Sampson S, Adams CE. Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders. Cochrane Database Syst Rev. 2014;(6):CD001470. doi: 10.1002/14651858.CD001470.pub2.
43. Zyprexa [package Insert]. Indianapolis (IN): Eli Lilly and Company;2018.
44. Fefeu M, De Maricourt P, Cachia A, Hoertel N, Vacheron MN, et al. One-year mirror-image study of the impact of olanzapine long-acting injection on healthcare resource utilization and costs in severe schizophrenia. Psychiatry Res. 2018;270:205-210. doi: 10.1016/j.psychres.2018.09.041.
45. Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Berg- strom RF. Olanzapine long-acting injection: a 24-week, ran- domized, double-blind trial of maintenance treatment in pa- tients with schizophrenia. Am J Psychiatry. 2010;167(2):181-9. doi: 10.1176/appi.ajp.2009.07081221.
Review
For citations:
Bibekova Zh.B., Strel’cov E.A., Makarchuk A.S. APPLICATION OF ANTIPSYCHOTICS OF LONG-TERM ACTION IN SCHIZOPHRENIA. Medical Herald of the South of Russia. 2020;11(1):6-13. (In Russ.) https://doi.org/10.21886/2219-8075-2020-11-1-6-13
Views:
12825
Email this article 